Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 107,264 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Clear all
Completed No phase listed Observational

CTCs in Cervix Cancer

NCT04064515
View directory record Official record
Conditions
Cervical Cancer, HPV
Interventions
Blood Assayed for CTCs
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 30, 2026, 10:01 PM EDT
No Longer Available No phase listed Expanded access

Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma

NCT02715843
View directory record Official record
Conditions
Non-Hodgkin's B-cell Lymphoma
Interventions
MT-3724
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 30, 2026, 10:01 PM EDT
Not yet recruiting Not applicable Interventional

Miniature In-line Respirator

NCT07768215
View directory record Official record
Conditions
Brain Death, Respiration, Artificial
Interventions
Hope inVent
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
1 Year to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 10:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

NCT03537508
View directory record Official record
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine, Pneumococcal 13-valent conjugate vaccine, Pentavalent rotavirus vaccine, Hepatitis B vaccine, Measles, mumps, rubella (MMR) vaccine, Varicella vaccine, Hepatitis A vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,627 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
65
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 30, 2026, 10:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sickle Cell Pro-Inflammatory Response to Interval Training Study

NCT03653676
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Exercise Test (CIIT)
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Years to 21 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 30, 2026, 10:01 PM EDT
Withdrawn Not applicable Interventional

Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease

NCT00459225
View directory record Official record
Conditions
Anemia
Interventions
Iron (ferrous sulfate)
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 2 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 30, 2026, 10:01 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

NCT03564340
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
Interventions
Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

Study of CA-008 (Vocacapsaicin) in Bunionectomy Patients

NCT03599089
View directory record Official record
Conditions
Post-surgical Pain
Interventions
CA-008, Placebo, Ketorolac, Acetaminophen, Oxycodone, Bupivacaine Hydrochloride
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Pasadena, California • Pasadena, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 30, 2026, 10:01 PM EDT
Terminated Phase 2Phase 3 Interventional

Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients

NCT00622089
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
DIO-902
Drug
Lead sponsor
DiObex
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
12
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Oct 30, 2026, 10:01 PM EDT
Terminated Phase 1 Interventional

Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)

NCT00074750
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia
Interventions
DTGM
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 30, 2026, 10:01 PM EDT
Active, not recruiting No phase listed Observational

Obi Medical Robot: Evaluating Effectiveness Related to Usability

NCT07151950
View directory record Official record
Conditions
Upper Extremity Impairments, Cerebral Palsy (CP), ALS - Amyotrophic Lateral Sclerosis, Rett Syndrome
Interventions
One-week trial of Obi Medical device, which provides robotic assistance with feeding to persons with upper extremity impairments who are unable to self-feed in the traditional manner using utensils
Device
Lead sponsor
Desin LLC
Industry
Eligibility
5 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 30, 2026, 10:01 PM EDT
Recruiting No phase listed Observational

Pivotal Study for the Cardiac Performance System (CPS)

NCT06870591
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Cardiac Performance System (CPS)
Device
Lead sponsor
Sensydia Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Timeline
2025 – 2026
U.S. locations
10
States / cities
Huntsville, Alabama • Evanston, Illinois • Hackensack, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 30, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

NCT03496974
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Bermekimab Monoclonal Antibody 200 mg, Bermekimab Monoclonal Antibody 400 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 30, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction

NCT00062374
View directory record Official record
Conditions
Gastric Adenocarcinoma, Stage II Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer
Interventions
Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Fluorothymidine F-18, Irinotecan Hydrochloride, Positron Emission Tomography, Therapeutic Conventional Surgery
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 30, 2026, 10:01 PM EDT
Completed No phase listed Observational

A Study to Evaluate Conceptual Saturation of Evaluating Respiratory Symptoms (E-RS) in Subjects With Asthma

NCT03344406
View directory record Official record
Conditions
Asthma
Interventions
Telephonic interviews, E-RS: COPD, Supplemental asthma items, Daily diary, Sociodemographic questionnaire, Clinical questionnaire
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 30, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

An Extension to Study MD7108240

NCT00733304
View directory record Official record
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 30, 2026, 10:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

NCT06134804
View directory record Official record
Conditions
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Interventions
ExPEC9V, Placebo, HD quadrivalent influenza vaccine
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
959 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
24
States / cities
Huntsville, Alabama • Mobile, Alabama • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 30, 2026, 10:01 PM EDT
Terminated Not applicable Interventional Results available

Effects of Neuro-Stim System on Pain, Sleep, and Opioid Use

NCT02673684
View directory record Official record
Conditions
Pain (Visceral, Somatic, or Neuropathic)
Interventions
Experimental NSS, Sham NSS
Device
Lead sponsor
Defense and Veterans Center for Integrative Pain Management
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 30, 2026, 10:01 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

NCT02688933
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
99
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 80 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 30, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

NCT01986933
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
nemolizumab (CIM331), Placebo
Drug · Other
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
18
States / cities
Anniston, Alabama • San Diego, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 30, 2026, 10:01 PM EDT
Recruiting Phase 3 Interventional

Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)

NCT05174052
View directory record Official record
Conditions
Diabetes Mellitus, Atrial Fibrillation
Interventions
Dapagliflozin 10Mg Tab, Placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 30, 2026, 10:01 PM EDT
Withdrawn Phase 2 Interventional

Intravenous (IV) Lidocaine for Opioid-refractory Pain

NCT00321347
View directory record Official record
Conditions
Neoplasms, Pain
Interventions
Lidocaine
Drug
Lead sponsor
San Diego Hospice & Palliative Care
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 30, 2026, 10:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigation of Cecal Intubation Rates and Pain Levels Between Water Exchange and Air Insufflation Flexible Sigmoidoscopy

NCT03209349
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Water Exchange Sigmoidoscopy, Air Insufflation Sigmoidoscopy
Procedure
Lead sponsor
Kelowna Gastroenterology Associates
Other
Eligibility
50 Years to 74 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
North Hills, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 30, 2026, 10:01 PM EDT
Active, not recruiting Not applicable Interventional

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

NCT05701358
View directory record Official record
Conditions
Acute Myocardial Infarction, Coronary Artery Disease
Interventions
Physiology-guided NCL PCI, Angiography-guided NCL PCI
Procedure
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
5,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Wichita, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 10:01 PM EDT